The global stem cell umbilical cord blood market was valued at $3,110.8 million in 2019, and is projected to reach $10,135.20 million by 2027, registering a CAGR of 16.9% from 2020 to 2027. Presently, the global stem cell market dominates the healthcare industry with its reliable and cost-effective methods of treatment and fewer side effects. The umbilical cord blood stem cell segment is one of the potential segments of the stem cell market, which is projected to grow in the future. Cord blood is one of the rich sources of stem cells, which are treated as waste after pregnancy or childbirth; however, this blood has huge potential to treat chronic diseases such as cancer, diabetes, and blood disease immune diseases.
Currently, more than 80 genetic diseases can be treated with cord blood and the blood is rich source of hematopoietic stem cells. Various governments are supporting the research and clinical trials of cord blood stem cells, which is has increased the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. However, competition in the market is intense with companies trying to create brand awareness, therefore, compelling market players to adopt many market-based strategies. These stem cells are the only type of cells that are stored in controlled conditions due to their lower volume and higher cell count.
Cost structure of the stem cell treatment has a major impact on the growth of the market in developed countries. Stem cells collected from cord blood is used in treatment of many rare diseases that include metabolic diseases and immune diseases. The overall stem cell umbilical cord blood market is growing from clinical applications to commercialization. Companies involved in the research and commercialization of stem cell therapies are adopting approval and clinical trials as their primary strategy and product launch as their secondary strategy.
Based on the storage services, the market is segmented into private cord blood banks, public cord blood banks and hybrid cord blood banks. The private cord banks segment was the highest contributor to the market, with $1,537 million in 2019, and is estimated to reach $4,765.90 million by 2027, at a CAGR of 15.3% during the forecast period. Based on therapeutics, the market is categorized into Cancer, Diabetes, Blood diseases, Immune disorders, Metabolic disorders and other diseases. The diabetes segment was the highest contributor to the market, with $794 million in 2019, and is estimated to reach $2,655.58 million by 2027, at a CAGR of 16.4% during the forecast period. Based on application, the market is categorized into transplant medicine and regenerative medicine. The regenerative medicine segment was the highest contributor to the market, with $1,854.12 million in 2019, and is estimated to reach $5,878.55 million by 2027, at a CAGR of 15.6% during the forecast period. The stem cell umbilical cord blood market is more lucrative in North America and European countries. Most patents granted for cord blood were from the U.S. and European authorities. North America shared the largest revenue of $1,353.20 million in 2019, however Asia-Pacific is expected to grow at CAGR of 16.7% CAGR during the forecast period. The companies offering stem cell umbilical cord blood storage services include Cordlife Group Limited, Cord Blood America, Cryo-Cell International, Medipost, Global Cord Blood Corporation, Americord Registry, and Cordvida.
Key Benefits for Stakeholders
Key Market Segments
By Storage services
By Therapeutics
By Application
By Region
Key players in the market
Cost structure of the stem cell treatment has a major impact on the growth of the market in developed countries. Stem cells collected from cord blood is used in treatment of many rare diseases that include metabolic diseases and immune diseases. The overall stem cell umbilical cord blood market is growing from clinical applications to commercialization. Companies involved in the research and commercialization of stem cell therapies are adopting approval and clinical trials as their primary strategy and product launch as their secondary strategy.
Based on the storage services, the market is segmented into private cord blood banks, public cord blood banks and hybrid cord blood banks. The private cord banks segment was the highest contributor to the market, with $1,537 million in 2019, and is estimated to reach $4,765.90 million by 2027, at a CAGR of 15.3% during the forecast period. Based on therapeutics, the market is categorized into Cancer, Diabetes, Blood diseases, Immune disorders, Metabolic disorders and other diseases. The diabetes segment was the highest contributor to the market, with $794 million in 2019, and is estimated to reach $2,655.58 million by 2027, at a CAGR of 16.4% during the forecast period. Based on application, the market is categorized into transplant medicine and regenerative medicine. The regenerative medicine segment was the highest contributor to the market, with $1,854.12 million in 2019, and is estimated to reach $5,878.55 million by 2027, at a CAGR of 15.6% during the forecast period. The stem cell umbilical cord blood market is more lucrative in North America and European countries. Most patents granted for cord blood were from the U.S. and European authorities. North America shared the largest revenue of $1,353.20 million in 2019, however Asia-Pacific is expected to grow at CAGR of 16.7% CAGR during the forecast period. The companies offering stem cell umbilical cord blood storage services include Cordlife Group Limited, Cord Blood America, Cryo-Cell International, Medipost, Global Cord Blood Corporation, Americord Registry, and Cordvida.
Key Benefits for Stakeholders
- This report entails a detailed quantitative analysis along with the current stem cell umbilical cord blood trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
- The market forecast is studied from 2020 to 2027.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
Key Market Segments
By Storage services
- Public Cord Blood Banks
- Private Cord Blood Banks
- Hybrid Cord Blood Banks
By Therapeutics
- Cancer
- Diabetes
- Blood Diseases
- Immune Disorders
- Metabolic Disorders
- Other Diseases
By Application
- Transplant Medicine
- Regenerative Medicine
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key players in the market
- Cordlife Group Limited
- Cord Blood America
- Cryo-Cell International
- Medipost
- Americord Registry
- Esperite
- China Cord Blood Corporation
- LifeCell Inetrnational
- ViaCord
- Vita34 AG
| Report Attribute | Details |
|---|---|
| No. of Pages | 209 |
| Published | August 2020 |
| Forecast Period | 2019 - 2027 |
| Estimated Market Value in 2019 | 1353.2 million |
| Forecasted Market Value by 2027 | 4765.9 million |
| Compound Annual Growth Rate | 17.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Stem Cell Umbilical Cord Blood Market, by Storage Serivces
Chapter 5: Stem Cell Umbilical Cord Blood Market, by Therapeutics
Chapter 6: Stem Cell Umbilical Cord Blood Market, by Application
Chapter 7: Stem Cell Umbilical Cord Blood Market, by Region
Chapter 8: Company Profiles
Companies Mentioned
- Americord Registry LLC
- China Cord Blood Corporation
- Cordlife Group Limited
- Cord Blood America, Inc.
- Cryo-Cell International, Inc.
- Esperite N. V.
- Lifecell International Pvt. Ltd.
- Medipost Co. Ltd.
- Viacord
- Vita34 AG
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
